Zobrazeno 1 - 10
of 295
pro vyhledávání: '"Edith P. Mitchell"'
Publikováno v:
Cancer Medicine, Vol 13, Iss 3, Pp n/a-n/a (2024)
Abstract This review describes the barriers and challenges faced by older adults of color with cancer and highlights methods to improve their overall care. In the next decade, cancer incidence rates are expected to increase in the United States for p
Externí odkaz:
https://doaj.org/article/13bdde2cb43d46019cba7627d4579dfe
Autor:
Christina L. Tamargo, Edith P. Mitchell, Lynne Wagner, Melissa A. Simon, Ruth C. Carlos, Bruce J. Giantonio, Matthew B. Schabath, Gwendolyn P. Quinn
Publikováno v:
Frontiers in Psychology, Vol 13 (2022)
BackgroundWhile societal acceptance for sexual and gender minority (SGM) individuals is increasing, this group continues to face barriers to quality healthcare. Little is known about clinicians’ experiences with SGM patients in the oncology setting
Externí odkaz:
https://doaj.org/article/81d1324a47e448248d6b7634fd9577cd
Publikováno v:
Frontiers in Public Health, Vol 10 (2022)
ObjectiveReal-world data characterizing differences between African American (AA) and White women with metastatic triple-negative breast cancer (mTNBC) are limited. Using 9 years of data collected from community practices throughout the United States
Externí odkaz:
https://doaj.org/article/547aff7185b94ef7a778bdd663860e05
Publikováno v:
Cancer Research. 83:P4-07
Purpose: Epidemiologic and clinical evidence have shown an association between obesity and increased risk for breast cancer (BC) incidence and mortality. Data from human and animal studies support a potential role for weight loss in counteracting tum
Autor:
Lubna N. Chaudhary, Inna Chervoneva, Amy R. Peck, Yunguang Sun, Misung Yi, John F. Langenheim, Julie M. Jorns, Sailaja Kamaraju, Yee Chung Cheng, John Burfeind, Christopher R. Chitambar, Jeffrey A. Hooke, Albert J. Kovatich, Craig Shriver, Hai Hu, Juan P. Palazzo, Marluce Bibbo, Terry Hyslop, Richard Pestell, Edith P. Mitchell, Hallgeir Rui
Publikováno v:
Cancer Research. 83:P2-11
Background PD-1 inhibitors have shown significant efficacy in triple negative breast cancer (BC), however, durable responses are less common in estrogen receptor-positive (ER+) BC. Better markers are therefore needed that will identify likely respond
Autor:
Amy S. Clark, Fangxin Hong, Richard S. Finn, Angela M. DeMichele, Edith P. Mitchell, James Zwiebel, Fernanda I. Arnaldez, Robert J. Gray, Victoria Wang, Lisa M. McShane, Larry V. Rubinstein, David Patton, P. Mickey Williams, Stanley R. Hamilton, Mehmet S. Copur, Samer S. Kasbari, Ravneet Thind, Barbara A. Conley, Carlos L. Arteaga, Peter J. O'Dwyer, Lyndsay N. Harris, Alice P. Chen, Keith T. Flaherty
Publikováno v:
Clinical Cancer Research. 29:1477-1483
Purpose: Cyclin D/CDK4/6 is critical in controlling the G1 to S checkpoint. CCND, the gene encoding cyclin D, is known to be amplified in a variety of solid tumors. Palbociclib is an oral CDK4/6 inhibitor, approved in advanced breast cancer in combin
Autor:
Philippe L. Bedard, Shuli Li, Kari B. Wisinski, Eddy S. Yang, Sewanti A. Limaye, Edith P. Mitchell, James A. Zwiebel, Jeffrey A. Moscow, Robert J. Gray, Victoria Wang, Lisa M. McShane, Larry V. Rubinstein, David R. Patton, P. Mickey Williams, Stanley R. Hamilton, Barbara A. Conley, Carlos L. Arteaga, Lyndsay N. Harris, Peter J. O'Dwyer, Alice P. Chen, Keith T. Flaherty
Publikováno v:
JCO precision oncology. 6
PURPOSE National Cancer Institute–Molecular Analysis for Therapy Choice is a multicohort trial that assigns patients with advanced cancers to targeted therapies on the basis of central tumor genomic testing. Arm B evaluated afatinib, an ErbB family
Autor:
Senthil, Damodaran, Fengmin, Zhao, Dustin A, Deming, Edith P, Mitchell, John J, Wright, Robert J, Gray, Victoria, Wang, Lisa M, McShane, Larry V, Rubinstein, David R, Patton, P Mickey, Williams, Stanley R, Hamilton, Jennifer M, Suga, Barbara A, Conley, Carlos L, Arteaga, Lyndsay N, Harris, Peter J, O'Dwyer, Alice P, Chen, Keith T, Flaherty
Publikováno v:
J Clin Oncol
Activating mutations in PIK3CA are observed across multiple tumor types. The NCI-MATCH (EAY131) is a tumor-agnostic platform trial that enrolls patients to targeted therapies on the basis of matching genomic alterations. Arm Z1F evaluated copanlisib,
Autor:
Shannon Stockton, Paul Catalano, Steven J Cohen, Barbara A Burtness, Edith P Mitchell, Efrat Dotan, Sam J Lubner, Pankaj Kumar, Mary F Mulcahy, George A Fisher, Theodore L Crandall, Al Benson
Publikováno v:
The Oncologist.
Background Patients with advanced esophageal cancer carry poor prognoses; limited data exist to guide second-line therapy in the metastatic setting. Paclitaxel has been used yet is associated with limited efficacy. There is preclinical evidence of sy
Autor:
Keith T. Flaherty, Alice P. Chen, Lyndsay N. Harris, Peter J. O'Dwyer, Carlos L. Arteaga, Barbara A. Conley, Ravneet Thind, Samer S. Kasbari, Mehmet S. Copur, Stanley R. Hamilton, P. Mickey Williams, David Patton, Larry V. Rubinstein, Lisa M. McShane, Victoria Wang, Robert J. Gray, Fernanda I. Arnaldez, James Zwiebel, Edith P. Mitchell, Angela M. DeMichele, Richard S. Finn, Fangxin Hong, Amy S. Clark
Representativeness of Study Participants
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::93e238d00836438710bd3e04e5688eb2
https://doi.org/10.1158/1078-0432.22633064.v1
https://doi.org/10.1158/1078-0432.22633064.v1